LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: A prospective randomized study

European Heart Journal

Volumn 24, Issue 14, 2003, Pages 1287-1295

  Cotter, Gad ^a,b   Kaluski, Edo ^a,b   Milo, Olga ^a,b   Blatt, Alex ^a,b   Salah, Ahmed ^a,b   Hendler, Alberto ^a,b   Krakover, Rikardo ^a,b   Golick, Ahuva ^a,b   Vered, Zvi ^a,b  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cardiogenic Shock; Nitric Oxide; NO synthase inhibitors

Indexed keywords

DOPAMINE; FUROSEMIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HUMAN; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFRACTORY CARDIOGENIC SHOCK; STATISTICAL ANALYSIS;

AGED; ENZYME INHIBITORS; FEMALE; HUMANS; INTRA-AORTIC BALLOON PUMPING; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PROSPECTIVE STUDIES; SHOCK, CARDIOGENIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0042405194     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(03)00193-3     Document Type: Article

References (25)

1. Hochman JS, Sleeper LA, Sanborn TA et al. Early revasularization in acute myocardial infarctioncomplicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999;341:625-34.
2. Cotter G, Fincke R, Lowe A et al. Hemodynamic Parameters in Cardiogenic Shock due to Myocardial Infarction: A Report from the SHOCK Trial Registry. Eur J Heart Fail. Abstract (in press).
3. Cotter G, Moshkovitz Y, Kaluski E et al. The Role of Cardiac Power and Systemic Vascular Resistance in The Pathophysiology and Diagnosis of Patients with Acute Congestive Heart Failure. Eur J Heart Fail (in press).
4. Ignarro LJ. Nitric oxide-mediated vasorelaxation. Thromb. Hemost. 1997;70:148-51.
5. Liu JL, Zucker IH. Regulation of symapthetic nerve activity in heart failure: a role for nitric oxide and angiotensin II. Circ Res 1999;84:417-23.
6. Owalya R, Vollenweider L, Trueb L et al. Cardiovascular and sympathetic effects of nitric oxide inhibition at rest and during static exercise in humans. Circulation 1997; 96:3897-903.
7. Flesch M, Kilter H, Cremers B et al. Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. J Pharmacol Exp Ther 1997;28:1340-9.
8. Kodja G, Kottenberg K, Nix P et al. Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocites. Circ Res 1996;78:91-101.
9. Mohan P, Brutsaert DL, Paulus WJ et al. Myocardial contractile response to nitric oxide and cGMP. Circulation 1996; 93:1223-9.
10. Depré C, Vanoverschelde J-L, Goudemant J-F et al. Protection Against Ischemic Injury by Nonvasoactive Concentrations of Nitric Oxide Synthase Inhibitors in the Perfused Rabbit Heart. Circulation 1995;92:1911-8.
11. Feng O, Lu X, Jones DL et al. Increased Inducible Nitric Oxide Synthase Expression Contributes to Myocardial Dysfunction and Higher Mortality After Myocardial Infarction in Mice. Circulation 2001;104:700-4.
12. Sam F, Sawyer DB, Xie Z et al. Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction. Circ Res 2001;89:351-6.
13. Cotter G, Kaluski E, Blatt A et al. L-NMMA (a nitric oxyde synthase inhibitor) is effective in the treatment of cardiogenic Shock. Circulation 2000;101:1358-61.
14. Cotter G, Moshkovitz Y, Milovanov O et al. Acute Congestive Heart Failure: A Novel Approach to Its Pathogenesis and Treatment (Review). Eur J Heart Failure 2003;4:227-34.
15. Williams SG, Cooke GA, Wright DJ et al. Peak exercise cardiac power output. A direct indicator of cardiac function strongly predictive of prognosis in chronic heart failure. Eur Heart J 2001; 22:1496-503.
16. The TIMI Study Group. The Thrombolysis in Myocardial infarction (TIMI) trial. N Engl J Med 1985;31:932-6.
17. Gibson CM, Murphy SA, Rizzo MJ et al. The relationship between the TIMI frame count and clinical outcomes after thrombolytic administration. Circulation 1999;99:1945-50.
18. Gibson CM, Cannon CP, Murphy SA et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of therombolytic drugs. Circulation 2000; 101:125-30.
19. Webb JG, Sanborn TA, Sleeper LA et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial registry. Am Heart J 2001;141:964-70.
20. Sanchez de Miguel L, Arriero MM, Farre J et al. Nitric oxide production by neutrophils obtained from patients during acute coronary syndromes: expression of the nitric oxide synthase isoforms. J Am Coll Cardiol 2002;39:818-25.
21. Zhang Y, Bissing JW, Xu L et al. Nitric oxide synthase inhibitors decrease coronary sinus-free radical concentration and ameliorate myocardial stunning in an ischemia-reperfusion model. J Am Coll Cardiol 2001;38:546-54.
22. Bruner F, Andrew P, Wolkart G et al. Myocardial Contractile Function and Heart Rate in Mice With Myocyte-Specific Overexpression of Endothelial Nitric Oxide Synthase. Circulation 2001;104:3097-102.
23. Ziolo MT, Katoh H, Bers DM. Expression of Inducible Nitric Oxide Synthase Depresses β-Adrenergic-Stimulated Calcium Release From the Sarcoplasmic Reticulum in Intact Ventricular Myocytes. Circulation 2001;104:2961-6.
24. Karunanithi MK, Young JA, Kalnins W et al. Response of the intact canine left ventricle to increased afterload and increased coronary perfusion pressure in the presence of coronary flow autoregulation. Circulation 1999; 100:1562-8.
25. Cobb JP. Use of nitric oxide synthase inhibitors to treat septic shock: The light has changed from yellow to red. Crit Care Med 1999;27:855-6.